TOP 1630

Drug Profile

TOP 1630

Alternative Names: TOP1630

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TopiVert
  • Class Anti-inflammatories
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Protein kinase inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 15 Jun 2017 Topivert Pharma completes a phase II trial in Dry eyes in USA (NCT03088605)
  • 20 Feb 2017 Phase-II clinical trials in Dry eyes in USA (Topical) (NCT03088605)
  • 28 Nov 2016 US FDA approves IND application for TOP 1630 in Dry eye
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top